Infusions deliver medications, fluids, or nutrients directly into the bloodstream through a vein, and people receive them for dozens of different medical reasons. The common thread is that the oral route either cannot work, cannot work fast enough, or cannot deliver a high enough dose of whatever the body needs. From chemotherapy and antibiotics to iron replacement and immune-modulating drugs, infusion therapy spans nearly every branch of medicine, and the number of conditions treated this way has grown steadily over the past few decades.
Bypassing the Digestive System
The most fundamental reason infusions exist is a pharmacological reality called the first-pass effect. When you swallow a pill, the drug travels through your stomach and small intestine, gets absorbed into the blood, and then passes through the liver before reaching the rest of your body. Along the way, the liver and intestinal enzymes break down a portion of the drug before it ever has a chance to do its job. For some medications, this breakdown is so extensive that only a fraction of the original dose makes it into general circulation. Giving the same drug intravenously sidesteps that process entirely, which is why IV doses are often lower than what you would need to take by mouth for the same effect.1Canadian Society of Pharmacology and Therapeutics. Glossary of Pharmacology – Section: First-pass Effect
Speed matters too. In an emergency, waiting for a pill to dissolve, absorb, and circulate can mean losing critical minutes. An IV line gets medication into the bloodstream almost immediately, which is why emergency rooms rely heavily on infusions for pain control, seizure management, blood pressure crises, and allergic reactions. And for certain large, complex molecules like monoclonal antibodies, the digestive system would simply destroy them before they could work. These proteins need to be infused because there is no oral form that survives the gut.
Iron Deficiency and Nutritional Support
Iron-deficiency anemia is one of the most common reasons people receive infusions outside of a hospital. Oral iron supplements are the default first step, but they come with well-known problems: nausea, constipation, and slow absorption that can take months to correct a deficiency. For people with inflammatory bowel disease, chronic kidney disease, heavy menstrual bleeding, or postpartum anemia, oral iron often falls short. A systematic review and meta-analysis of 31 clinical trials comparing oral and intravenous iron found that IV iron typically produced a faster and more substantial rise in hemoglobin and ferritin, especially in conditions where iron requirements are high or gut absorption is limited.2PubMed Central. Efficacy of oral vs. intravenous iron for the treatment of iron deficiency anemia in different conditions: A systematic review and meta-analysis
Beyond iron, some people rely on infusions for their entire nutritional intake. Intestinal failure, most commonly caused by short bowel syndrome, leaves the gut unable to absorb enough nutrients to sustain health. Short bowel syndrome develops when large sections of the small intestine are removed surgically or damaged by conditions like Crohn’s disease or blood-supply loss to the intestine.3PubMed. Indications for intestinal transplantation: recognizing the scope and limits of total parenteral nutrition For these patients, parenteral nutrition, a carefully formulated IV mixture of sugars, amino acids, fats, vitamins, and minerals, becomes the primary treatment, sometimes for life.4PubMed. Chronic intestinal failure: Medical treatment, home parenteral nutrition, training and monitoring Some patients’ intestines adapt over time and regain enough function to reduce or stop the infusions, but many remain dependent on parenteral nutrition long-term.5PubMed Central. Parenteral Nutrition and Intestinal Failure
Autoimmune and Inflammatory Diseases
Autoimmune conditions are among the fastest-growing reasons for infusion therapy. In these diseases, the immune system attacks the body’s own tissues, and the drugs that can slow or stop that attack are often large protein-based molecules, biologics, that must be infused.
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, was among the first autoimmune conditions to be transformed by infused biologic therapies. Infliximab, one of the earliest monoclonal antibody treatments, works by binding to a key inflammatory protein called TNF-alpha, blocking it from triggering the cascade of inflammation that damages the intestinal lining.6Hong Kong Pharmaceutical Journal. Review of Monoclonal Antibodies for the Treatment of Crohn’s Disease – Section: USE OF MONOCLONAL ANTIBODIES(mABs) IN CD The arrival of these therapies fundamentally changed outcomes for people with IBD.7PubMed Central. Recent advances in monoclonal antibody therapy in IBD: practical issues
Rheumatoid arthritis follows a similar pattern. When conventional pills fail to control the disease, guidelines recommend moving to biologic therapies, many of which are given as infusions. TNF inhibitors like infliximab, along with other infused biologics that target different parts of the immune pathway, are standard options for patients with high disease activity who haven’t responded to first-line oral medications.8PubMed Central. The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Intravenous immunoglobulin, or IVIg, occupies its own category. It is a concentrated solution of antibodies pooled from thousands of blood donors, and it is used to treat a range of neurological and immunological conditions. IVIg works through multiple mechanisms at once: it can neutralize harmful autoantibodies, dampen complement activation, and shift the balance of inflammatory signaling in the immune system.9PubMed Central. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy Conditions treated with IVIg include Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and certain immune deficiency disorders.
Cancer Treatment
Chemotherapy is probably the first thing most people picture when they think of infusion therapy. Many chemotherapy drugs are harsh on veins and tissues, and early administration through peripheral veins caused problems like vascular damage and drug leaking into surrounding tissue. Implantable venous access ports, small devices surgically placed under the skin and connected to a large central vein, became the standard solution. These ports allow chemotherapy to be infused safely over extended periods and have been shown to be reliable for long-term use.10PubMed Central. Safety of immediate use of totally implantable venous access ports in adult patients with cancer: a retrospective single-center study
Beyond traditional chemotherapy, a newer class of cancer drugs, immune checkpoint inhibitors, has expanded the role of infusions in oncology. These are monoclonal antibodies that essentially take the brakes off the immune system, allowing it to recognize and attack cancer cells. The FDA has approved several categories of these drugs, including PD-1 inhibitors like nivolumab and pembrolizumab, PD-L1 inhibitors like atezolizumab and durvalumab, and the CTLA-4 inhibitor ipilimumab. They have been used successfully in patients with metastatic melanoma, kidney cancer, head and neck cancers, and lung cancer, among others.11PubMed Central. Immune Checkpoint Inhibitors in Cancer Therapy Like biologics for autoimmune disease, these are large proteins that cannot survive the digestive tract and must be infused.
Multiple Sclerosis and Neurological Conditions
Multiple sclerosis is a condition where infusion therapy has made a dramatic difference. Ocrelizumab, an infused monoclonal antibody that targets a specific type of immune cell involved in the nerve-damaging inflammation of MS, has become a leading treatment option. In two large clinical trials, ocrelizumab reduced the annualized relapse rate by about 46 to 47 percent compared to a standard injectable MS drug.12PubMed Central. Ocrelizumab: A Review in Multiple Sclerosis For patients with highly active relapsing-remitting MS, the results can be even more striking: one study found the annualized relapse rate dropped from 2.24 before treatment to 0.058 during the observation period.13PubMed. Ocrelizumab as first-line therapy in highly active relapsing-remitting multiple sclerosis
Ocrelizumab is given as an infusion every six months, which also simplifies the treatment schedule compared to daily pills or frequent injections. But it is just one example. Natalizumab, another infused monoclonal antibody, is used for MS and Crohn’s disease. And the IVIg treatments discussed in the autoimmune section are a mainstay in neuromuscular conditions where the immune system attacks peripheral nerves or the junction between nerves and muscles.
Infections and Acute Care
Serious infections often require IV antibiotics because the drugs need to reach high concentrations in the blood quickly and reliably. Bone and joint infections, heart valve infections, deep-seated abscesses, and bloodstream infections are commonly treated with IV antibiotics that would not reach effective levels if taken by mouth. Interestingly, many of these patients do not need to stay in the hospital for the full course. Outpatient parenteral antibiotic therapy, or OPAT, allows patients to receive their IV antibiotics at home or in an outpatient clinic. A systematic review of randomized trials found that OPAT is a safe and effective alternative to staying in the hospital.14PubMed. Safety and efficacy of outpatient parenteral antimicrobial therapy: A systematic review and meta-analysis of randomized clinical trials
One large Australian hospital’s OPAT program handled over 3,400 referrals across a decade, totaling more than 25,000 antibiotic days delivered outside the hospital. Skin and soft tissue infections were the most common reason, making up about 61 percent of referrals, followed by bone and joint infections at roughly 15 percent. Readmission rates were low overall, around 5 percent.15PubMed. Outpatient parenteral antibiotic therapy in a suburban tertiary referral centre in Australia over 10 years Programs like these free up hospital beds while keeping patients in their own homes, which matters both for quality of life and for reducing healthcare costs.
On the acute care side, IV fluids for dehydration remain one of the most basic and widespread uses of infusion therapy. For severely dehydrated patients, especially young children or people who cannot keep fluids down, intravenous rehydration delivers water, electrolytes, and glucose directly into the circulation. A systematic review of IV rehydration in severely malnourished and dehydrated children found a trend toward lower in-hospital mortality with IV rehydration compared to oral rehydration, and a reduced risk of dangerously low sodium levels at 24 hours.16PubMed Central. Intravenous rehydration in children with severe malnutrition and severe dehydration: a systematic review and meta-analysis
Osteoporosis and Bone Health
Osteoporosis treatment might seem like an unlikely candidate for infusion therapy, but a once-yearly infusion of zoledronic acid has become an important option. Zoledronic acid is a bisphosphonate, a class of drugs that strengthens bone by slowing the cells that break it down. The oral versions of bisphosphonates have strict dosing requirements: they need to be taken on an empty stomach, with the patient remaining upright for 30 to 60 minutes afterward. Many patients find these instructions difficult to follow consistently, and poor adherence means the drug does not work as well as it should.
Zoledronic acid is given as a 15-minute infusion once a year, which eliminates the adherence problem entirely. One infusion covers a full 12 months of treatment.17PubMed Central. Zoledronic acid infusion for prevention and treatment of osteoporosis A landmark trial found that three annual infusions of zoledronic acid significantly reduced the risk of vertebral fractures, hip fractures, and other fractures in postmenopausal women.18PubMed. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis Patients tend to prefer the annual infusion schedule over daily or weekly pills, and adherence improves as a result.19PubMed Central. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates
Pain Management and Mental Health
Infusions play a role at both ends of the pain spectrum. In palliative and end-of-life care, continuous morphine infusions are used to manage pain and shortness of breath when patients can no longer swallow pills or when their pain requires steady, uninterrupted delivery of medication.20PubMed Central. Variable Patterns of Continuous Morphine Infusions at End of Life These infusions can be delivered through a small pump that runs continuously, providing comfort without requiring the patient to take anything by mouth.
On the mental health side, ketamine infusions have emerged as a treatment for depression that has not responded to standard antidepressants. Ketamine, long used as an anesthetic, was found to produce rapid antidepressant effects, sometimes within hours, in people with treatment-resistant depression. Research suggests this rapid effect may be related to ketamine’s ability to increase the number and function of connections between neurons in brain areas affected by depression and chronic stress.21PubMed Central. The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review The speed of that response is part of what makes ketamine notable: traditional antidepressants typically take weeks to show full effects, while ketamine can produce measurable mood improvement in a single session. Ketamine clinics have proliferated in recent years, though questions about optimal dosing, long-term use, and which patients benefit most are still being worked out.
Home Infusion Therapy
A growing number of infusions now happen outside hospitals and clinics. Home infusion therapy has expanded to cover IV antibiotics, parenteral nutrition, immunoglobulin therapy, and even some biologic medications. This shift matters because it changes how the treatment fits into someone’s life. A study comparing home infusion patients with those treated in medical facilities found that home patients were no more likely to experience adverse drug events or side effects. Clinical outcomes were as good or better, and for patients with hemophilia specifically, home infusion was associated with a 40 percent lower likelihood of hospitalization for bleeding complications. Patients overwhelmingly preferred being treated at home, reporting better physical and mental well-being and less disruption to their daily lives. Home infusion costs were also significantly lower, with savings between roughly $1,900 and $3,000 per treatment course.22PubMed. Home infusion: Safe, clinically effective, patient preferred, and cost saving
Safety data for home immunoglobulin infusions are reassuring as well. A retrospective analysis of over 1,100 patients receiving IVIg at home for neurological and immunological conditions found it was safe and well tolerated, with few serious adverse reactions.23PubMed. A Retrospective Analysis of the Safety Profile of Intravenous Immunoglobulin in 1176 Patients Receiving Home Infusion Therapy For patients on chronic infusion regimens, the ability to receive treatment at home rather than spending hours in an infusion center every few weeks can make a substantial difference in quality of life.
Managing Infusion Reactions
One real concern with infusion therapy is the possibility of an infusion-related reaction. Because many infused drugs are large proteins derived from biological sources, the immune system sometimes reacts to them. Symptoms can range from mild, like flushing, itching, or a headache, to more serious, like drops in blood pressure or difficulty breathing. These reactions are most common during the first few infusions and tend to become less frequent over time as the body adjusts.
Healthcare teams have developed standard protocols to reduce these risks. Premedication with acetaminophen, antihistamines, and sometimes corticosteroids is routine before many biologic infusions, and these measures reduce both the frequency and severity of reactions.24PubMed Central. The importance of early identification of infusion-related reactions to monoclonal antibodies – Section: Infusion-related reactions: prevention and treatment Modified premedication approaches continue to improve outcomes. For ocrelizumab, the MS drug discussed earlier, a modified premedication protocol significantly reduced the odds of infusion-associated reactions.25PubMed. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol Infusion centers also control the rate at which drugs are delivered: starting slowly and gradually increasing the speed gives the body time to tolerate the medication, and slowing or pausing the infusion at the first sign of a reaction is standard practice.
The risk of a serious reaction is generally low, but it is part of why most infusions, at least initially, are supervised by trained nurses who monitor vital signs throughout the session. For patients who tolerate their first several infusions without trouble, the transition to home infusion or faster infusion rates often becomes an option, reflecting the individualized nature of how infusion therapy evolves over time for each person.